Decision Resources Group anticipates the next ten years to be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to grow. Existing agents fail to provide sustained and intrinsic control of T1D, and none address the autoimmune component of T1D’s etiology. While late-stage pipeline therapies in development represent drug classes already on the market (e.g., SGLT-2 inhibitors), several early-stage pipeline therapies present genuine novel mechanisms of action. There is a shifting emphasis on the types of therapies in development for T1D, with significant interest in pancreatic beta-cell replacement therapies and CD3 antigen inhibitors. The launch of biosimilar insulins is having a profound effect on the T1D market across the G7, and we are witnessing an intricate interplay of physician and payer attitudes to this new treatment option.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 20 country-specific interviews with thought-leaders and endocrinologists. Patient shares surveyed in all regions.
Epidemiology: Diagnosed prevalence; 3 drug-treated subpopulations modeled— adult, adolescent, and child.
Emerging therapies: Phase II: 30+ drugs; Phase III: 7 drugs; preregistration: 2 drugs. Coverage of select preclinical and Phase I products.
Market forecast features: Using a proprietary model, we forecast population sizes and T1D drug sales for rolled-up adult, adolescent, and child patient segments through 2026.
Key companies: Novo Nordisk, Sanofi, Eli Lilly, Merck, Boehringer Ingelheim, Samsung Bioepis, Mylan, Biocon, Astellas, Janssen, Bristol-Myers Squibb, AstraZeneca, Lexicon, Sanofi
Key drugs: Lantus, Levemir, Toujeo, Tresiba, Abasaglar, NovoLog, Humalog, Fiasp, Admelog, Ryzodeg, Jardiance, Farxiga, Invokana, Suglat, sotagliflozin.